{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T22:35:15Z","timestamp":1768084515076,"version":"3.49.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:sec>\n            <jats:title>Study Objective:<\/jats:title>\n            <jats:p>To study dapsone in comparison with trimethoprim\/sulfamethoxazole (TMP\/SMX) for Pneumocystis jiroveci (PJP) prophylaxis in children with acute lymphoblastic leukemia (ALL).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Design:<\/jats:title>\n            <jats:p>A retrospective study with a prospective follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients:<\/jats:title>\n            <jats:p>Pediatric ALL patients diagnosed between May 2009 and May 2014, who are still receiving or have completed their maintenance chemotherapy. Patients who completed chemotherapy were prospectively followed up for neutropenia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>TMP\/SMX was used as the initial PJP prophylaxis. An alternative drug was indicated if the patient remained cytopenic for &gt;3 weeks. Average absolute neutrophilic count (ANC), average % of oral mercaptopurine (6-MP), and methotrexate doses were calculated over a period of 6 months before and after shifting to dapsone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Sixty-two ALL patients were eligible for analysis. Twenty-four patients (38.7%) received TMP\/SMX for PJP prophylaxis, whereas 34 patients received Dapsone (54.8%). Only 3 patients received IV pentamidine (4.8%), whereas 1 patient (1.6%) received atovaquone. The incidence of prophylaxis failure was 1\/1041 months on TMP\/SMX and 1\/528 months on dapsone. After shifting to dapsone, patients maintained significantly higher ANC (1.46\u00b10.46 vs. 1.17\u00b10.40, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.0053), and received significantly higher doses of 6-MP (62.61%\u00b111.45 vs. 57.45\u00b110.14, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.0081) and methotrexate (64.9%\u00b114.29 vs. 56.5%\u00b19.9, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.0176), with a significantly shorter duration of chemotherapy interruption (1.94\u00b11.2 vs. 3.25\u00b11.29 wk, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.0002).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Dapsone for PJP prophylaxis in ALL allowed patients to maintain higher ANC and to receive higher doses of chemotherapy, while maintaining a low incidence of PJP breakthrough infection.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mph.0000000000000804","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T15:29:39Z","timestamp":1487950179000},"page":"203-208","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and Safety of Dapsone Versus Trimethoprim\/Sulfamethoxazol for Pneumocystis Jiroveci Prophylaxis in Children With Acute Lymphoblastic Leukemia With a Background of Ethnic Neutropenia"],"prefix":"10.1097","volume":"39","author":[{"given":"Hanan F.","family":"Nazir","sequence":"first","affiliation":[{"name":"Child Health Department"},{"name":"Department of Pediatrics, Faculty of Medicine, University of Alexandria, Alexandria, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Elshinawy","sequence":"additional","affiliation":[{"name":"Child Health Department"},{"name":"Department of Pediatrics, Faculty of Medicine, University of Alexandria, Alexandria, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulhakim","family":"AlRawas","sequence":"additional","affiliation":[{"name":"Child Health Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doaa","family":"Khater","sequence":"additional","affiliation":[{"name":"Child Health Department"},{"name":"Department of Pediatrics, Faculty of Medicine, University of Alexandria, Alexandria, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherin","family":"Zadjaly","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Sultan Qaboos University Hospital, Muscat, Oman"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasser","family":"Wali","sequence":"additional","affiliation":[{"name":"Child Health Department"},{"name":"Department of Pediatrics, Faculty of Medicine, University of Alexandria, Alexandria, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.prrv.2009.06.010","article-title":"Pneumocystis pneumonia in children","volume":"10","author":"Pyrgos","year":"2009","journal-title":"Paediatr Respir Rev"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/mpo.1157","article-title":"Pneumocystis carinii pneumonia during maintenance treatment of childhood acute lymphoblastic leukemia","volume":"37","author":"Poulsen","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MPH.0b013e3181fd6fca","article-title":"Twice weekly Pneumocystis jiroveci pneumonia prophylaxis with trimethoprim-sulfamethoxazole in pediatric patients with acute lymphoblastic leukemia","volume":"33","author":"Agrawal","year":"2011","journal-title":"J Pediatr Hematol Oncol"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2165\/00148581-200709050-00003","article-title":"Management of Pneumocystis jiroveci pneumonia in children receiving chemotherapy","volume":"9","author":"Shankar","year":"2007","journal-title":"Paediatr Drugs"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/bmt.2016.133","article-title":"IV pentamidine for Pneumocystis jiroveci pneumonia prophylaxis in pediatric allogeneic stem cell transplant patients","volume":"51","author":"Curi","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/tid.12486","article-title":"Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation","volume":"18","author":"Diri","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/tid.12457","article-title":"Efficacy of once-weekly dapsone dosing for Pneumocystis jirovecii pneumonia prophylaxis post transplantation","volume":"17","author":"Evans","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1600-0609.2011.01695.x","article-title":"Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate\/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia","volume":"88","author":"Levinsen","year":"2012","journal-title":"Eur J Haematol"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/bjh.13847","article-title":"Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003","volume":"172","author":"Hough","year":"2016","journal-title":"Br J Haematol"},{"key":"R10-20230918","first-page":"625","article-title":"The Genetics of Benign Neutropenia","volume":"13","author":"Paz","year":"2011","journal-title":"IMAJ"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.imlet.2003.10.003","article-title":"Lymphocyte subsets in healthy adult Kuwaiti Arabs with relative benign ethnic neutropenia","volume":"91","author":"Kaaba","year":"2004","journal-title":"Immunol Lett"},{"key":"R12-20230918","first-page":"3","article-title":"Prevalence, phenotype and inheritance of benign neutropenia in Arabs","volume":"9","author":"Denic","year":"2009","journal-title":"BMC Blood Disord"},{"key":"R13-20230918","first-page":"275","article-title":"Agranulocyosis in beta thalassemia major patients treated with oral iron chelating agent (deferiprone)","volume":"23","author":"Wali","year":"2008","journal-title":"OMJournal"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1200\/JCO.2009.24.3881","article-title":"Neutrophil count in African Americans: lowering the target cutoff to initiate or resume chemotherapy?","volume":"28","author":"Hsieh","year":"2010","journal-title":"J Clin Oncol"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1651-2227.1984.tb17772.x","article-title":"Early and late neutropenia in children treated with cotrimoxazole (trimethoprim-sulfamethoxazole)","volume":"73","author":"Principi","year":"1984","journal-title":"Acta Paediatr Scand"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"e74171","DOI":"10.1371\/journal.pone.0074171","article-title":"Cotrimoxazole prophylaxis and risk of severe anemia or severe neutropenia in HAART-exposed, HIV-uninfected infants","volume":"8","author":"Peterson","year":"2013","journal-title":"PLOS one"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0002-9343(96)00008-3","article-title":"Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim\/sulfamethoxazole","volume":"100","author":"Beumont","year":"1996","journal-title":"Am J Med"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.bbmt.2005.04.011","article-title":"Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study","volume":"11","author":"Sangiolo","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1345\/aph.1Q139","article-title":"Dapsone-induced methemoglobinemia: a primer for clinicians","volume":"45","author":"Barclay","year":"2011","journal-title":"Ann Pharmacother"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/bmt.2011.83","article-title":"High prevalence of dapsone-induced oxidant hemolysis in North American SCT recipients without glucose-6-phosphate-dehydrogenase deficiency","volume":"47","author":"Olteanu","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/pbc.20164","article-title":"Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for pneumocystis carinii pneumonia (PCP) prophylaxis: a correlation with cytochrome b5 reductase (Cb5R) enzyme levels","volume":"44","author":"Williams","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1002\/cncr.25904","article-title":"Dapsone-induced methemoglobinemia: a dose-related occurrence?","volume":"117","author":"Esbenshade","year":"2011","journal-title":"Cancer"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/jcpt.12060","article-title":"Methotrexate and trimethoprim-sulphamethoxazole: extremely serious and life-threatening combination","volume":"38","author":"Al-Quteimat","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0022-3476(05)83351-7","article-title":"Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia","volume":"117","author":"Ferrazzini","year":"1990","journal-title":"J Pediatr"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJM197712292972602","article-title":"Successful chemoprophylaxis for Pneumocystis carinii pneumonitis","volume":"297","author":"Hughes","year":"1977","journal-title":"N Engl J Med"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jpeds.2013.10.021","article-title":"Single-day trimethoprim\/sulfamethoxazole prophylaxis for pneumocystis pneumonia in children with cancer","volume":"164","author":"Caselli","year":"2014","journal-title":"J Pediatr"},{"key":"R27-20230918","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1086\/514626","article-title":"Use of dapsone in the prevention and treatment of pneumocystis carinii pneumonia: a review","volume":"27","author":"Hughes","year":"1998","journal-title":"Clin Infect Dis"},{"key":"R28-20230918","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/MPH.0000000000000206","article-title":"Mercaptopurine\/methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction","volume":"36","author":"Schmiegelow","year":"2014","journal-title":"J Pediatr Hematol Oncol"},{"key":"R29-20230918","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/08880019109028803","article-title":"Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia","volume":"8","author":"Schmiegelow","year":"1991","journal-title":"Pediatr Hematol Oncol"},{"key":"R30-20230918","first-page":"123","article-title":"Management of Pneumocystis jirovecii pneumonia in HIV infected patients: current options, challenges and future directions","volume":"2","author":"Castro","year":"2010","journal-title":"HIV AIDS (Auckl)"},{"key":"R31-20230918","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/archinte.162.8.921","article-title":"Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines","volume":"162","author":"Goldie","year":"2002","journal-title":"Arch Intern Med"},{"key":"R32-20230918","first-page":"CD005590","article-title":"Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients","volume":"10","author":"Stern","year":"2014","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201704000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T05:03:31Z","timestamp":1695013411000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201704000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000000804","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}